Alpha Tau Medical (NASDAQ:DRTS) Stock Falls 7.4% – Here’s What Happened

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) fell 7.4% on Thursday. The stock traded as low as $11.34 and last traded at $11.1190. Approximately 251,251 shares changed hands during trading, a decline of 57% from the average session volume of 585,250 shares. The stock had previously closed at $12.01.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DRTS. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, November 9th. Piper Sandler raised Alpha Tau Medical from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $8.00 to $22.00 in a report on Wednesday, November 11th. UBS Group restated a “buy” rating on shares of Alpha Tau Medical in a research report on Tuesday. Wall Street Zen raised Alpha Tau Medical from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Alpha Tau Medical in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.20.

Check Out Our Latest Stock Analysis on Alpha Tau Medical

Alpha Tau Medical Price Performance

The firm has a market cap of $1.06 billion, a P/E ratio of -11.30 and a beta of 1.28. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $13.79 and its two-hundred day moving average is $11.03.

Hedge Funds Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Everhart Financial Group Inc. acquired a new position in Alpha Tau Medical during the 2nd quarter valued at about $126,000. Principal Financial Group Inc. purchased a new position in shares of Alpha Tau Medical during the 1st quarter valued at $132,000. Finally, Renaissance Technologies LLC bought a new position in Alpha Tau Medical in the 1st quarter worth about $286,000. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.

Further Reading

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.